Paper36929658
Metformin and thymoquinone co-treatment enhance 5-fluorouracil cytotoxicity by suppressing the PI3K/mTOR/HIF1α pathway and increasing oxidative stress in colon cancer cells.
Farrash WF and 12 others. Biofactors, 2023. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Metformin and thymoquinone co-treatment enhance 5-fluorouracil cytotoxicity by suppressing the PI3K/mTOR/HIF1α pathway and increasing oxidative stress in colon cancer cells. Papers, record 36929658. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36929658
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metformin and thymoquinone co-treatment enhance 5-fluorouracil cytotoxicity by suppressing the PI3K/mTOR/HIF1α pathway and increasing oxidative stress in colon cancer cells.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colonic Neoplasms | Major topic |
| Fluorouracil | Major topic |
| Metformin | Major topic |
| Humans | |
| Apoptosis | |
| bcl-2-Associated X Protein | |
| Caspase 3 | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Cytochromes | |
| Oxidative Stress | |
| Phosphatidylinositol 3-Kinases | |
| Proliferating Cell Nuclear Antigen | |
| Proto-Oncogene Proteins c-akt | |
| Survivin | |
| TOR Serine-Threonine Kinases | |
| Hypoxia-Inducible Factor 1, alpha Subunit | |
| Benzoquinones |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| IFP22UQU4320045DSR101 | The Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia | PubMed |
Source PubMed
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42396351 | Irisin Potentiates 5-fluorouracil Cytotoxicity in HT-29 Colon Cancer Cells through Enhanced Apoptosis and Transcriptional Modulation of Adenosine Monophosphate-activated Protein Kinase/Mammalian Target of Rapamycin Signaling. | Int J Appl Basic Med Res | 2026 | https://conductscience.org/library/papers/42396351 | PubMed |
| 42389271 | Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42389271 | PubMed |
| 41002741 | Diagnostic and Therapeutic Value of the Exercise-Induced Myokine Irisin in Cancer Biology: A Comprehensive Review. | Diseases | 2025 | https://conductscience.org/library/papers/41002741 | PubMed |
| 40299210 | Increased protein expression of interleukin-10 and its signalling molecules in colon cancer progression: potential prognostic and therapeutic targets. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40299210 | PubMed |
| 40264514 | Metformin Enhances the Chemosensitivity of Gastric Cancer to Cisplatin by Downregulating Nrf2 Level. | Anal Cell Pathol (Amst) | 2025 | https://conductscience.org/library/papers/40264514 | PubMed |
| 40059278 | Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation. | J Egypt Natl Canc Inst | 2025 | https://conductscience.org/library/papers/40059278 | PubMed |
| 39839894 | Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/39839894 | PubMed |
| 39405607 | Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance. | Transl Oncol | 2024 | https://conductscience.org/library/papers/39405607 | PubMed |
| 39337420 | Effect of Sodium-Glucose Co-Transporter 2 Inhibitors Combined with Metformin on Pancreatic Cancer Cell Lines. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337420 | PubMed |
| 39309188 | Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/39309188 | PubMed |
| 38791419 | Additive Cytotoxic and Colony-Formation Inhibitory Effects of Aspirin and Metformin on PI3KCA-Mutant Colorectal Cancer Cells. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38791419 | PubMed |
| 38248312 | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer. | Curr Issues Mol Biol | 2023 | https://conductscience.org/library/papers/38248312 | PubMed |
| 38087345 | Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/38087345 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36929658
GET https://conductscience.org/api/papers/v1/36929658/authors